Skip to main content
. 2023 Jul 10;120(29):e2303740120. doi: 10.1073/pnas.2303740120

Fig. 4.

Fig. 4.

Tumor growth and angiogenesis in anti-VEGF- and anti-ANG2-treated KRAS mutant PDAC tumors. (A) Tumor growth rates of BxPC3 KRAS wt and KRAS mutant PDAC tumors (n = 5 to 8 tumors per group). (B) Tumor growth rates of vehicle-, anti-VEGF-, anti-ANG2-, anti-VEGF plus anti-ANG2-treated BxPC3 KRAS wt and KRAS mutant PDAC tumors (n = 5 to 8 tumors per group). Vehicle-treated controls are the same as those in A. (C and D) CD31+ tumor microvessels (red) and NG2+ pericytes (green) in various antibody-treated BxPC3 KRAS wt (C) and KRAS mutant (D) PDAC tumors. (E and F) Quantification of microvessels and pericyte coverage in various antibody-treated BxPC3 KRAS wt (E) and KRAS mutant (F) tumors (n = 10 fields per group). All data represent mean ± SEM. (Scale bar, 50 μm.) Statistical analysis was performed using two-sided unpaired t tests (A and B) and one-way ANOVA followed by Tukey’s multiple comparison tests (E and F). **P < 0.01, ***P < 0.001. N.S., not significant.